Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
In this study, investigators aimed to evaluated the efficacy and safety of microwave ablation
combined with anlotinib and TQB2450 Solution in patients with advanced hepatocellular
carcinoma. Patients were randomly assigned at a one-to-one ratio to receive microwave
ablation plus anlotinib and TQB2450 Solution or microwave ablation plus TQB2450 Solution.
Primary end points were objective response rate(ORR). Second end points include overall
survival, progression-free survival and disease control rate. Safety was assessed in all
patients.